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The diabetic subjects with prolonged QT interval in electrocardiogram associated with autonomic 
neuropathy may die suddenly and unexpectedlyl-3l. Thus， the QT interval prolongation has been 
suggested to predict cardiovascular mortality not only in healthy population but also in diabetes 
mellitus with autonomic neuropathy4，5l. 1na previous study6l， we reported that the QTc interval in 
diabetic subjects treated with glibenclamide， one of hypoglycemic sulfonylurea drugs， was signifi聞
cantly longer than that treated with diet alone independently of diabetic autonomic neuropathy， and 
that glibenclamide treatment has been suggested to prolong the QT interval. Because of being 
simple and crosssectional， the previous study has remained equivocal results. Therefore， we made 
sure by the investigation of the QTc-interval change during two years if it is true or not that the 
prolongation in diabetic subjects occurs by glibenclamide. 
Materials and methods 
Subjects 
Ninety-one subjects (aged 50-70 yr) with non輔insulindependent diabetes mellitus were enrolled for 
the study， inwhom the mode of therapy (for insulin， sulfonylureas， or diet) had not been changed 
over the last two years. Their diabetic condition was stable， and they were treated neither with 
diuretics， digitalis，β-blockers， nor antiarrhythmic drugs that could potentially interfere with the 
QT interval. They had no hypertension or abnormal findings on the electrocardiogram monitoring 
[recent or past myocardial infarction， right or left ventricular hypertrophy (RV 4> 45 min)， arrhyth-
mias， or ST-T changes]. Thirty幽onesubjects had been treated with insulin， 34with sulfonylureas (20 
with glibenc1amide and 14 with glic1azide)， and 26 with diet alone. Clinical features of the subjects 
were shown in Table l. 
M easurements 01 QT interval 
All subjects had received every year a standard 12-1ead electrocardiogram. 1n them， 91 subjects 
with QTc-interval of 380-420 msec were selected from the ECG records in 1992. The records in 1992 
were compared with those in 1994. The longest QT interval was measured in leads 1， 11， or IL 
which consists of the length from the first deflection of the QRS complex to the end of the T top， 
where it merges with the electric baseline. Adjustment for heart rate was made according to 
Bazett's formula: QTc=QT/JRR6l. Coefficient of variation for the R-R interval (CVR-R) was 
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determined from 150 systoles by the off岨linecalculator of an R-R interval measuring device. 
Statistical analyses 
The data were expressed as the means土SD.Analysis of variance was used and twoωtailed 
Student's nonpaired t test was also used for statistical evaluations. 
Results 
The age and the duration of diabetes were not significantly different from those among the four 
groups as shown in Table 1. The prevalence of diabetic complications was higher in diabetic subjects 
treated with insulin or sulfonylureas than in those treated with diet alone. HbA1 c value in diabetic 
subjects treated with insulin was significantly higher than that treated with diet alone. CV R-Rin 
diabetic subjects treated with insulin (1.78:10.80%) was significantly lower than that treated diet 
alone (2.68士1.22%).QTc interval was not significantly different among the four groups， although 
the.QTc interval in the subject treated with gliclazide was slightly longer than in other groups. 
Table 1 Clinical features of non-insulin dependent diabetes mellitus 
i nsu I i n diet g I i benc I am i de g I i c Iaz i de 
(n=31) (n=26) (n=20) (n=14) 
age(yr) 61. 916. 2 62. 4士5.7 61. 8士5.6 61. 616. 4 
duration of 
diabetes (yr) 17.3士7.4 12. 9土7.2 13.717. 1 12.818.2 
peripheral 
neuropathy 26/31 15/26 16/20 9/14 
retinopathy 20/31 7/26 12/20 6/14 
nephropathy 10/31 5/26 4/20 3/14 
serum K (mEq/l) 4.610.4 4.4土0.4 4. 610. 3 4. 510. 3 
serum Ca (mg/dl) 8.310.6 8. 510. 6 8. 610. 5 8. 510. 5 
HbA，c(児)
1992 8.712. 1本 7.411. 0 7.8土0.9 7. 6土1.1 
1994 9. 012. 2 7.4土1.1 7.9土1.1 8. 111. 2 
CVR-R(目) 1.78土0.80本 2. 68土1.22 2. 22土0.80 2.36土0.88
QTc(msec) 
1992 410土27 410土25 413土12 411土23
1994 417土20 416土31 415士1 421131 
The data are expressed as means土SD.
本pく0.05. significantly different from diet. 
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Discussion 
The present study clear1y demonstrated that the QTc interval gradually and naturally prolonged 
in diabetic subjects， and that the sulfonylurea drugs did not influence the prolongation of the QTc 
interval. The present results were contradictory to the result of our previous report that the QTc 
interval was significantly longer in the diabetic subject treated with glibenclamide6l. Our previous 
report was a cross“sectional study， and it is possible that diabetic subjects who initially had 
prolonged QTc interval were included in glibenclamide働treateddiabetic groups. Thus， the reexami-
nation of our previous study revealed that three subjects who initially had prolonged QTc interval 
(> 420 msec) were included in glibenclamide-treated groups although such subjects were not 
included in diet-or insulin-treated groups. This may mainly be responsible for the previous results. 
We conclude that sulfonylurea drugs do not enhance the naturallengthening of the QTc interval 
in NIDDM subjects. 
Summary 
In a previous study， we reported that QTc interval in diabetic subjects treated with glibenclamide， 
one of hypoglycemic sulfonylurea drugs， was significantly longer than that treated with diet alone 
independently of diabetic autonomic neuropathy. We pursued the two years QTc-interval changes in 
diabetic subjects to elucidate whether or not glibenclamide lengthen the interval. Ninety-one 
subjects (aged 50-70 yr) with non-insulin dependent diabetes mellitus were enrolled for the study， who 
had received unchanged therapy (for insulin， sulfonylureas， or diet) over the last two years. The 
subjects were divided into four groups; 1) 31 subjects treated with insulin， 2)20 with glivenclamide， 
3) 14 with gliclazide， and 4) 26 with diet alone. After 2 years， there were no significant differences 
in the QTc interval among the four groups， although the QTc interval naturally and slightly 
prolonged in al groups during the same periods. 
These results suggest that sulfonylurea drugs do not enhance the naturallengthening of the QTc 
interval in NIDDM subjects. 
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